Clinical Trials Browser

Completed × Neoplasms, Plasma Cell × Dexamethasone × Clear all

NCT01208766 2026-01-06

HO95

Phase 3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07206810 2025-10-03

A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients

Neoplasms, Plasma Cell

NCT03773107 2025-01-13

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

Phase 1/2 Completed

12 enrolled 19 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00482261 2024-11-08

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

Phase 2 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00305812 2023-08-04

Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00002878 2023-06-15

Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02186834 2023-01-04

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

Phase 1/2 Completed

28 enrolled 10 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00054158 2022-10-03

Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02424851 2022-01-27

OPTIMAL

Phase 2 Completed

31 enrolled 13 charts

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

NCT04065789 2022-01-27

KyDaR

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00075829 2021-11-01

BMT CTN 0102

Phase 3 Completed

710 enrolled 19 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00792142 2021-08-19

Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Phase 2 Completed

45 enrolled 8 charts

Multiple Myeloma, Neurotoxicity Syndromes, Neoplasms, Plasma Cell

NCT00538733 2021-05-24

T-BiRD

Phase 2 Completed

26 enrolled 16 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01237951 2020-05-05

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Phase 2 Completed

75 enrolled 11 charts

Neoplasms, Plasma Cell

NCT01497093 2020-04-07

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00002678 2020-04-02

Combination Chemotherapy in Treating Patients With Multiple Myeloma

Phase 3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01023308 2020-03-17

PANORAMA-1

Phase 3 Completed

767 enrolled 17 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00772915 2020-01-18

Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Completed

39 enrolled 13 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00003399 2019-10-17

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00003401 2019-10-17

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00049374 2019-10-17

Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02188537 2019-06-26

Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma

Phase 2 Completed

Neoplasms, Plasma Cell

NCT01440582 2019-03-04

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

Phase 1 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00038090 2018-10-31

Thalidomide-Dexamethasone for Multiple Myeloma

Phase 2/3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01861340 2018-09-10

Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma

Phase EARLY_PHASE1 Completed

Neoplasms, Plasma Cell

NCT00558896 2018-04-18

CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis

Phase 2 Completed

378 enrolled 13 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02103335 2017-11-22

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

Phase 1 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02419118 2017-11-07

DARA

Phase 2/3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01042704 2017-07-31

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

Phase 1 Completed

Neoplasms, Plasma Cell

NCT01432600 2017-05-23

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

Phase 1/2 Completed

80 enrolled 12 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00150462 2017-05-02

Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies

Phase 1 Completed

48 enrolled 26 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00458822 2016-08-10

Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis

Phase 2 Completed

40 enrolled 5 charts

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00477971 2016-05-17

Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

Phase 3 Completed

89 enrolled 11 charts

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00293384 2016-03-15

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

Phase NA Completed

40 enrolled 9 charts

BreastCNSDermatologicGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Testicular Germ Cell Tumor, Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Carcinoma, Ovarian Epithelial, Blast Crisis, Breast Neoplasms, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Leukemia, Hairy Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Myeloproliferative Disorders, Nausea, Neuroblastoma, Ovarian Neoplasms, Sezary Syndrome, Testicular Neoplasms, Vomiting, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Gestational Trophoblastic Disease, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00111748 2015-10-06

UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients

Phase 3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00064038 2015-03-25

S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma

Phase 3 Completed

198 enrolled 6 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00814541 2014-12-31

PAD. ICORG 05-01, V11

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00402181 2014-05-14

An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00033332 2014-04-04

Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00017602 2014-01-06

Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00416897 2013-08-26

Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure

Phase 3 Completed

Multiple Myeloma, Renal Insufficiency, Neoplasms, Plasma Cell

NCT00003493 2013-07-18

Combination Chemotherapy in Treating Patients With Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00021359 2013-07-10

Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00003007 2013-06-26

Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00006232 2013-05-15

Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma

Phase 3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00564889 2013-05-14

Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Phase 2 Completed

35 enrolled 11 charts

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00258245 2013-04-29

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Phase 1 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00008242 2013-03-07

Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00089167 2013-01-16

Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis

Phase 2 Completed

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00089453 2012-04-19

Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant

Phase 1 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell